Overview

Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease

Status:
Not yet recruiting

Trial end date:
2025-11-30

Target enrollment:

Participant gender:

Summary

The present study is aimed to determine the safety and efficacy of Ticagrelor single antiplatelet therapy (SAPT) in patients with primary coronary small vessel disease at high risk of bleeding after drug coated balloon (DCB) therapy.

Phase:

Phase 4

Details

Lead Sponsor:

Fu Wai Hospital, Beijing, China

Treatments:

Aspirin
Clopidogrel
Ticagrelor